ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

ANNALS OF ONCOLOGY driving innovation in oncology

CORRIGENDUM

Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers'

[Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]

G. Fossard[1,2,3], F. Broussais[1], I. Coelho[4], S. Bailly[5,6], E. Nicolas-Virelizier[7], E. Toussaint[8], C. Lancesseur[9], F. Le Bras[10], E. Willems[11], E. Tchernonog[12], T. Chalopin[13], R. Delarue[14], R. Gressin[15], A. Chauchet[16], E. Gyan[13], G. Cartron[12], C. Bonnet[11], C. Haioun[10], G. Damaj[9], P. Gaulard[10], L. Fornecker[8], H. Ghesquières[1], O. Tournilhac[5,6], M. Gomesda Silva[4], R. Bouabdallah[17], G. Salles[1,2,3] & E. Bachy[1,2,3]*

[1]Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite; [2]Claude Bernard Lyon 1 University, Lyon; [3]Cancer Center of Lyon (CRCL), INSERM U1052 – CNRS UMR5286, Lyon, France; [4]Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal; [5]Hematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France; [6]Clermont Auvergne University, Clermont-Ferrand; [7]Hematology Department, Centre Leon Berard, Lyon; [8]Hematology Department, CHU de Strasbourg, Strasbourg; [9]Hematology Institute, CHU de Caen, Caen; [10]Hematology Department, CHU Henri Mondor, Creteil, France; [11]Hematology Department, CHU de Liège, Liège, Belgium; [12]Hematology Department, CHU de Montpellier, Montpellier, France; [13]Hematology Department, CHU de Tours, Tours; [14]Hematology Department, CHU Necker Enfants Malades, AP-HP, Paris; [15]Hematology Department, CHU de Grenoble, Grenoble; [16]Hematology Department, CHU de Besançon, Besançon; [17]Hematology Department, Institut Paoli Calmette, Marseille, France

The authors regret that there is an error in the abstract. In the sentence "Among 527 patients screened from 14 centers in France, Belgium and Portugal, a final cohort of 269 patients ≤65 years old with PTCL-not otherwise specified (NOS) (N = 78, 29%), angioimmunoblastic T-cell lymphoma (AITL) (N = 123, 46%) and anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK-ALCL) (N = 68, 25%) with partial (N = 52, 19%) or complete responses (N = 217, 81%) after induction was identified and information about treatment allocation was carefully collected before therapy initiation from medical records", the term "anaplastic lymphoma kinase-positive anaplastic large cell lymphoma" should read "anaplastic lymphoma kinase-negative anaplastic large cell lymphoma".

The authors would like to apologise for any inconvenience caused.

DOI of original article: https://doi.org/10.1093/annonc/mdx787
*Correspondence to: E. Bachy.
E-mail: emmanuel.bachy@chu-lyon.fr (E. Bachy).